Q-omics provides the consensus-scored LY75-CD302 profile across patient tissues and cancer cell-line models. LY75-CD302 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, LY75-CD302 is differentially expressed in 7, with the highest sampling consensus in KICH. Additionally, LY75-CD302 RNA expression shows 12,179 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight SKCM, KICH, and ESCA as cancer lineages where LY75-CD302 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LY75-CD302 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LY75-CD302 survival associations across molecular data types. LY75-CD302 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LY75-CD302 RNA expression–survival associations across cancer types. High LY75-CD302 expression shows unfavorable associations in ACC, MESO, PAAD, LGG and COAD, but favorable associations in SKCM. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for LY75-CD302 RNA expression.
This table summarizes LY75-CD302 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for LY75-CD302. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LY75-CD302 shows lower tumor expression in KICH, COAD, THCA and LUSC and higher tumor expression in BLCA and KIRC. The KICH box plot shows higher LY75-CD302 RNA expression in normal versus tumor tissue (log2 FC = −0.028, t-test p < 0.001).
This table shows molecular features associated with LY75-CD302 in patient tissues and cancer cell lines. In patient samples, LY75-CD302 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, LY75-CD302 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and STOMACH.
